OSLO, Norway, Aug. 27, 2021 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage immuno-oncology company
developing immune activators to target hard-to-treat solid tumors,
today announces that the abstract "A pilot study of Engineered
Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in
checkpoint inhibitor refractory advanced or unresectable melanoma"
will be presented as an e-poster at the European Society for
Medical Oncology (ESMO) congress by Dr Alexander N. Shoushtari, Memorial Sloan
Kettering Cancer Center.
|
E-poster
title:
|
A pilot study of
Engineered Adenovirus ONCOS-102 in combination with pembrolizumab
(pembro) in checkpoint inhibitor refractory advanced or
unresectable melanoma
|
|
E-poster
number:
|
1083P
|
|
Presenter:
|
Dr Alexander N.
Shoushtari, Memorial Sloan Kettering Cancer Center
|
The abstract will be released on the ESMO website 13 September
00:05 CEST
(https://www.esmo.org/meetings/esmo-congress-2021). The results
from the completed phase 1 trial will be presented during the ESMO
congress 16-21 September 2021.
About ESMO
ESMO is the leading professional organisation for medical
oncology. With more than 23,000 members representing oncology
professionals from over 150 countries worldwide, ESMO is the
society of reference for oncology education and information. ESMO
is committed to offer the best care to people with cancer, through
fostering integrated cancer care, supporting oncologists in their
professional development, and advocating for sustainable cancer
care worldwide.
CONTACT:
For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--abstract-on-oncos-102-phase-1-trial-in-advanced-pd1-refractory-melanoma-is-accepted-at,c3404461